ResMed Toekomstige groei

Future criteriumcontroles 2/6

ResMed zal naar verwachting groeien in winst en omzet met respectievelijk 11.1% en 7.1% per jaar. De winst per aandeel zal naar verwachting groeien met 11.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 22% zijn.

Belangrijke informatie

11.1%

Groei van de winst

11.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.7%
Inkomstengroei	7.1%
Toekomstig rendement op eigen vermogen	22.0%
Dekking van analisten	Good
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

Recent updates

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24

Winst- en omzetgroeiprognoses

NYSE:RMD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	5,890	1,609	1,602	1,724	18
6/30/2026	5,494	1,471	1,501	1,595	21
6/30/2025	5,124	1,328	1,267	1,388	22
9/30/2024	4,807	1,113	1,347	1,441	N/A
6/30/2024	4,685	1,021	1,286	1,401	N/A
3/31/2024	4,584	958	1,071	1,199	N/A
12/31/2023	4,504	890	944	1,079	N/A
9/30/2023	4,375	907	792	935	N/A
6/30/2023	4,223	898	559	693	N/A
3/31/2023	4,016	863	408	535	N/A
12/31/2022	3,763	809	222	370	N/A
9/30/2022	3,624	786	305	461	N/A
6/30/2022	3,578	779	195	351	N/A
3/31/2022	3,539	779	344	498	N/A
12/31/2021	3,444	522	446	577	N/A
9/30/2021	3,349	500	397	527	N/A
6/30/2021	3,197	475	620	737	N/A
3/31/2021	3,091	457	733	840	N/A
12/31/2020	3,092	699	774	884	N/A
9/30/2020	3,028	680	684	784	N/A
6/30/2020	2,957	622	696	802	N/A
3/31/2020	2,892	513	505	614	N/A
12/31/2019	2,784	455	420	514	N/A
9/30/2019	2,699	419	487	573	N/A
6/30/2019	2,607	405	382	459	N/A
3/31/2019	2,525	446	374	447	N/A
12/31/2018	2,455	450	385	456	N/A
9/30/2018	2,405	335	390	459	N/A
6/30/2018	2,340	316	N/A	505	N/A
3/31/2018	2,273	307	N/A	516	N/A
12/31/2017	2,196	285	N/A	434	N/A
9/30/2017	2,125	352	N/A	422	N/A
6/30/2017	2,067	342	N/A	414	N/A
3/31/2017	2,029	324	N/A	417	N/A
12/31/2016	1,968	327	N/A	474	N/A
9/30/2016	1,893	346	N/A	510	N/A
6/30/2016	1,839	352	N/A	548	N/A
3/31/2016	1,773	357	N/A	505	N/A
12/31/2015	1,742	357	N/A	471	N/A
9/30/2015	1,710	353	N/A	421	N/A
6/30/2015	1,679	353	N/A	383	N/A
3/31/2015	1,641	353	N/A	399	N/A
12/31/2014	1,616	352	N/A	409	N/A
9/30/2014	1,578	348	N/A	387	N/A
6/30/2014	1,555	345	N/A	391	N/A
3/31/2014	1,554	331	N/A	400	N/A
12/31/2013	1,540	325	N/A	406	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei RMD ( 11.1% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van RMD ( 11.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.6% per jaar).

Hoge groeiwinsten: De winst van RMD zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van RMD ( 7.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van RMD ( 7.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen RMD zal naar verwachting over 3 jaar hoog zijn ( 22 %)

ResMed Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 7.3% to US$203

Price target decreased by 9.0% to US$195

Price target decreased by 7.7% to US$204

Price target decreased by 7.3% to US$214

Price target decreased by 9.3% to US$225

Recent updates

CEO & Chairman notifies of intention to sell stock

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

First quarter dividend of US$0.53 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 12, 2024

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

CEO & Chairman notifies of intention to sell stock

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health

Why ResMed's Rally Is Just Getting Started

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

CEO & Chairman notifies of intention to sell stock

ResMed Elects Christopher DelOrefice to the Board

CEO & Chairman notifies of intention to sell stock

Chief Product Officer recently sold US$10m worth of stock

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Fourth quarter dividend increased to US$0.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

CEO & Chairman notifies of intention to sell stock

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

CEO & Chairman notifies of intention to sell stock

Now 22% undervalued

CEO & Chairman notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Founder recently sold US$5.0m worth of stock

Founder notifies of intention to sell stock

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Price target increased by 7.3% to US$203

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

Why ResMed Is One Of My Top Picks In 2024

A First Look At ResMed

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

ResMed Secures Significant Victory in Patent Fight Against New York University

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Resmed Inc. Announces Board Changes

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Upcoming dividend of US$0.48 per share at 1.4% yield

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

Price target decreased by 9.0% to US$195

Price target decreased by 7.7% to US$204

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

Price target decreased by 7.3% to US$214

Price target decreased by 9.3% to US$225

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

CEO & Chairman notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 19%

ResMed Has Become A Steal (Rating Upgrade)